Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Brain Tumor Pathol. Author manuscript; available in PMC 2017 September 19.
Published in final edited form as:
PMCID: PMC5605295

High incidence of TERT mutation in brain tumor cell lines


TERT promoter gene mutations are highly recurrent in malignant glioma. However, little information exists regarding their presence in experimental brain tumor models. To better characterize systems in which TERT mutation studies could be appropriately modeled experimentally, the TERT promoter was examined by conventional sequencing in primary brain tumor initiating cells (BTIC), two matched recurrent BTIC lines, a panel of established malignant glioma cell lines, and two meningioma cell lines. Telomerase gene expression was examined by quantitative PCR. We found that all glioblastoma BTIC lines harbored a TERT mutation, which was retained in two patient-matched recurrent BTIC. The TERT C228T or C250T mutation was found in 33/35 (94 %) of established malignant glioma cell lines and both meningioma cell lines examined. Brain tumor cell lines expressed variably high telomerase levels. Thus, a high percentage of glioma cell lines, as well as two meningioma cell lines, harbors TERT mutations. These data characterize tractable, accessible models with which to further explore telomerase biology in these tumor types.

Keywords: TERT, Telomerase, Glioma, Glioblastoma, Meningioma, Brain tumor initiating cells, Cancer


Glioblastoma is the most aggressive primary brain tumor and carries a median survival of 12–14 months despite standard-of-care treatment [1]. To better understand its genomic landscape, extensive multi-platform genomic profiling approaches have been employed to characterize the somatic alterations that accumulate during the development of these tumors [24]. Collectively, these studies and others have revealed many of the recurrent genomic changes that underlie this cancer type. Of these, recurrent mutations in the promoter region of TERT are the most prevalent.

TERT encodes the catalytic subunit of the telomerase enzyme, which protects the telomeric ends of chromosomes and is considered necessary for human cellular transformation [5]. Additional extratelomeric roles for telomerase have also been described [6]. Telomerase is estimated to be overexpressed in 85–90 % of all human malignancies [7]. The recently discovered recurrent C➔T mutations at positions 1,295,228 and 1,295,250 (C228T and C250T, respectively) in the TERT promoter [8] lead to increased telomerase expression, likely due to the creation of novel ETS family transcription factor binding sites [8, 9]. Together, these mutations have been identified in over 80 % of glioblastomas [10] as well as a significant percentage of other malignancies including urothelial cancer, melanoma, basal cell carcinoma, and myxoid liposarcoma [11]. In fact, primary glioblastoma represents the malignancy with the highest incidence of this recurrent mutation to date, suggesting that its presence is crucial to tumor development and/or maintenance. Moreover, the presence of TERT mutations in the absence of concomitant IDH1 mutations portends a worse prognosis across all glioma grades [12, 13]. However, despite the critical importance of TERT mutations in glioblastoma, few in vitro glioblastoma models have been characterized to enable the study of this biology.

To identify in vitro experimental models of TERT-mutant brain tumors, we first annotated the TERT promoter mutation status in ten low-passage, patient-derived brain tumor initiating cells (BTIC) and provide the first evidence that these mutations are retained in patient-matched recurrent BTIC. We then characterized the TERT promoter mutation status in 35 well-studied glioblastoma cell lines as well as 2 meningioma cell lines and found that 35/37 (94.6 %) harbor either the C228T or C250T promoter mutation. TERT-mutated cell lines harbored high but variable levels of telomerase expression.

Materials and methods

Cell lines were obtained from 4 sources. Of 37 well-passaged cell lines, all but 6 were obtained from the Cancer Cell Line Encyclopedia [14]. IOMM-Lee, LN215, LN235, LN428, LN464, and SF767 were obtained from The RNAi Consortium, Broad Institute (Cambridge, MA). Normal human astrocytes were purchased from Lonza, Inc (Mapleton, IL). Brain tumor initiating cells (BTIC) were generated from patient specimens immediately ex vivo according to a previously described protocol [15]. Low-passage (≤5 passages from initial culture) BTICs were utilized for all experiments. Fluorescence in situ hybridization (FISH) and targeted cancer gene sequencing data were obtained as part of the clinical workflow at our institution.

The promoter region of the TERT gene was amplified by polymerase chain reaction using a modified previously described protocol [16]. Briefly, genomic DNA was isolated using the DNAeasy Blood and Tissue Kit (Qiagen). The region from 1,295,129 to 1,295,372 on chromosome 5 as annotated in the GRCh37 reference assembly was amplified from 200 to 300 ng of genomic DNA using the primers 5′-GCACAGACGCCCAGGACCGCGCT-3′ and 5′-TTCCCACGTGCGCAGCAGGACGCA-3′ [16] for 40 cycles using Taq polymerase (New England Biolabs) and 29 PCRx Enhancer Solution (Invitrogen) in a total volume of 50 μl. The TERT promoter amplicon was gel purified using the Qiaquick Gel Extraction Kit (Qiagen). Amplicons were sequenced using the above primers via conventional Sanger technology.

Telomerase expression levels were determined by quantitative RT-PCR. First-strand cDNA was synthesized from 1 μg of RNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Telomerase and GAPDH were amplified from 2 μl cDNA using TaqMan primers (assays Hs00972650 and Hs03929097, respectively, Applied Biosystems) for 40 cycles on an Eco Real-Time PCR System (Illumina).


Recent work has shown that malignant glioma harbors a high incidence of TERT mutations [10, 17]. To identify tractable models to study telomerase biology in this disease type, we first determined the incidence of TERT mutations by conventional Sanger sequencing technology in a subset of low-passage (≤5 passages from initial culture), patient-derived brain tumor initiating cells (BTIC) established at our institution from patients with primary (i.e., de novo) glioblastoma [15]. Nine of the ten lines characterized by clinical fluorescence in situ hybridization or gene panel sequencing exhibited alterations typically identified in primary glioblastoma, including loss of chromosome 10q or EGFR amplification (Table 1). Of ten BTIC lines derived from patients with an average age of 52.7 (38–66), nine harbored the C228T TERT mutation and one harbored the C250T mutations (Table 1). We then assessed whether the TERT mutation was retained in two patient-matched BTIC lines established from the recurrent glioblastomas in patients from whom the original BTIC lines, B2 and B28, were derived. Both patients received adjuvant radiation treatment, temozolomide, and were enrolled in the ACT IV trial. In both recurrent BTIC, termed “B2-Rc” and “B28-Rc”, the same TERT mutations were retained. These data show that TERT mutations are found not only in primary BTIC but also in patient-matched recurrent BTIC.

Table 1
TERT status in primary and recurrent glioblastoma BTIC

Having demonstrated that BTIC lines harbor a high incidence of TERT mutations, we extended our analysis and determined the incidence of TERT promoter mutations in a large panel of well-characterized and frequently studied glioma cell lines. Strikingly, 33/35 (94 %) of the analyzed cell lines harbored either the C228T or C250T mutation (Table 2), with 12/35 (34 %) carrying the C250T mutation compared to 21/35 (60 %) that possessed the C228T mutation. This distribution of mutations is consistent with previous studies in primary gliomas showing a relative predominance of the C228T mutation compared to C250T [12]. In the 2/35 (6 %) cell lines that were wild type, no alternative mutations were identified in the examined region of the promoter.

Table 2
TERT promoter status in malignant glioma and meningioma cell lines

Because additional studies show that meningiomas with TERT promoter mutations exhibit a significantly shorter time to recurrence [18] and a propensity to recur at a higher tumor grade [19], we also annotated the TERT promoter region in two well-studied meningioma cell lines. Both CH-157-MN and IOMM-Lee, which represent two of only a small panel of available meningioma cell lines, harbored the C228T TERT mutation (Table 2). Thus, most established, well-studied glioma and meningioma cell lines carry either the C228T or C250T TERT promoter mutations.

Because TERT promoter mutations are correlated with elevated telomerase expression, we examined the relative telomerase expression by quantitative RT-PCR in our panel of malignant glioma and meningioma cell lines as compared to normal human astrocytes (NHA), which harbor a wild-type TERT promoter sequence. TERT-mutant glioma cell lines expressed 2.2- to 286-fold higher telomerase expression relative to NHA (Fig. 1a). The 2 wild-type cell lines, CAS1 and SF172, exhibited telomerase expression that was 5.7-fold and 15.5-fold higher, respectively, than NHA as well. Meningioma cell lines expressed 145- to 400-fold higher telomerase expression relative to NHA (Fig. 1b). These results show that all TERT-mutant cell lines express a broad range of high levels of telomerase relative to untransformed astrocytes, and that well-passaged cell lines without the C228T/C250T mutations also express elevated telomerase levels (Fig. 1d).

Fig. 1
Telomerase gene expression in brain tumor cell lines. Telomerase gene expression was determined by quantitative RT-PCR in established malignant glioma cell lines (a), meningioma cell lines (b), and low-passage, patient-derived BTIC as well as 2 patient-matched ...

Finally, we examined telomerase gene expression in the BTIC lines. BTIC lines derived from newly diagnosed glioblastomas expressed 3.2- to 12.9-fold higher telomerase levels relative to NHA (Fig. 1c). Moreover, the two recurrent BTIC lines, B2-Rc and B28-Rc, expressed nearly sevenfold more telomerase than NHA. These data show that TERT-mutant BTIC harbor telomerase expression that is retained in patient-matched recurrences.


Herein, we annotated the region of the TERT promoter that harbors the highest percentage of recurrent mutations in a large panel of glioma cell lines, commonly studied meningioma cell lines, and a subset of BTIC. Gliomas have been found to exhibit the highest incidence of TERT promoter mutations across many cancer types, suggesting a major role of telomerase in tumor development and, likely, in tumor maintenance as well. In the short time since its discovery, TERT mutation status in glioma has also become a critical prognostic factor. Specifically, TERT mutations in both low-grade and high-grade IDH1 wild-type glioma portend a more aggressive natural history [13, 16, 20]. Conversely, TERT mutations concomitant with IDH1 mutations define a low-grade oligodendroglioma phenotype that presages the best prognosis for patients with these tumors. Thus, there is tremendous utility to the identification of accessible cell line models with TERT mutations to further study telomerase biology in glioma.

It is particularly important to characterize tractable in vitro models to study telomerase biology in brain tumors because its functions are complex. Although the effects of telomerase on telomere maintenance are well acknowledged, the recent observation that telomere length may be shorter in TERT-mutant gliomas compared to wild-type counterparts suggests that telomere lengthening functions may not be the only cancer-relevant function of this enzyme [12]. Indeed, prior work showed that immortalized cells could be transformed with a mutant telomerase unable to lengthen telomeres in vivo, providing experimental evidence that additional extratelomeric functions of this enzyme may be operative in the cancer setting [21]. Specifically, there appear to be possible telomere-independent roles for telomerase in regulating downstream Wnt signaling, in producing siRNAs through an RNA-dependent RNA polymerase function, and regulating apoptosis [6]. Further work is needed to clarify the physiologic relevance of these putative telomerase-dependent functions to the process of glioma formation and/or maintenance.

We found that nearly all of the cell lines we studied harbored either the C228T or C250T TERT promoter mutation, which correlated with variable levels of increased telomerase expression. While the high total percentage of TERT mutations in the 35 glioma cell lines reported herein (94 %) is consistent with the high incidence of TERT mutation seen in this disease type, there may also be a selection bias for TERT-mutant lines that may adapt well to cell culture over time. Our report thus provides the most comprehensive annotation of the TERT mutation status in a large panel of the most commonly studied glioma cell lines employed in the study of malignant glioma. A small subset of the malignant glioma cell lines we characterized have recently been shown to carry TERT promoter mutations [9, 2224], and our results are concordant with these findings.

It is notable that there appears to be a broad distribution of telomerase overexpression in our cell lines, as has been observed in other studies [12]. The higher levels of expression observed in some of the established glioma and meningioma cell lines may either mirror outliers observed in primary tumor samples or perhaps reflect a selection process for longstanding in vitro passage adaptation. Additional work will thus be necessary to determine both the etiologies and the consequences of the differences in the magnitudes of telomerase expression between tumors. Moreover, it will be important to consider the alternative mechanisms of telomerase overexpression in the absence of promoter mutations. In the case of the wild-type CAS-1 cell line, TERT is amplified and thus may be a possible mechanism that leads to increased telomerase expression relative to NHA. In other TERT wild-type settings, it is possible that elevated activation of some of the known transcriptional regulators of telomerase expression, such as c-Myc and b-catenin, may drive telomerase expression [25]. Additionally, epigenetic silencing of transcriptional repressors of telomerase may contribute to its regulation [11]. These mechanisms may also contribute to the high telomerase levels observed in the TERT-mutant context as well. It may also be important to consider the post-transcriptional regulation of the telomerase–holoenzyme complex. For instance, the assembly of the multi-component shelterin complex with the appropriate stoichiometry as well as its finely regulated trafficking within the nucleus is critical for telomerase function and provides additional points of cancer-relevant dysregulation that could augment telomerase activity in the absence of TERT promoter mutations or elevated telomerase transcription. Ongoing work is directed at exploring telomerase regulation in the glioma setting.

In addition to the well-established malignant glioma lines that we studied, we also characterized the TERT promoter mutations in primary patient-derived BTIC. Nine of ten BTIC harbored the C228T TERT promoter mutation, whereas one BTIC line carried the C250T mutation. Interestingly, in the two cases in which we also established BTIC from the patients’ glioblastoma recurrences, we also detected the same TERT mutations. While the preservation of TERT mutation was recently described [12], we provide the first evidence of TERT-mutant recurrent BTIC, suggesting a feasible method with which to study TERT mutation in primary and patient-matched recurrent settings. Although both recurrent BTIC exhibited decreased telomerase expression compared to their matched cell lines derived from newly diagnosed glioblastoma, additional work in larger paired samples will be needed to validate this trend and explore its biological relevance. It is unlikely that TERT mutation itself confers an advantage to establishing low-passage, patient-derived cultures because we have successfully established BTIC in over 90 % of our attempts.

Both meningioma cell lines we studied harbored TERT C228T mutations and exhibited significant levels of telomerase expression. Because primary, patient-derived meningioma cells are notoriously challenging to grow reliably and study in vitro, our data show that the CH-157-MN and IOMM-Lee cell lines—2 of only a small subset of cell lines commonly studied in meningioma biology—represent tractable models with which to study telomerase biology in this disease context. This line of study is particularly important because TERT mutation has been shown to correlate with a significantly shorter time to recurrence [18] as well transformation from lower grade to higher grade disease at time of recurrence [19].

In summary, we provide a comprehensive annotation of the TERT mutation status in a large panel of heavily studied malignant glioma cell lines, several well-characterized meningioma cell lines, and a panel of BTIC lines. Given the clear importance of recurrent TERT promoter mutations in these tumor types, further work using these cell line models will be important to better understand the contribution of TERT mutations to the cancer phenotype.


The authors thank Dr. Ravi Uppaluri for reviewing this manuscript and Dr. Jeffrey Atkinson for technical assistance. This work was supported by NIH grant K08NS092912 (G.P.D.), NIH Grant K08NS081105 (A.H.K.), American Cancer Society-Institutional Research Grant (A.H.K., G.P.D), the Duesen-berg Research Fund (A.H.K.), the Physician-Scientist Training Program at Washington University School of Medicine (T.M.J.), and the Brain Science Foundation (I.F.D.).


1. Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. [PubMed]
2. Network TCGA. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–1068. [PMC free article] [PubMed]
3. Brennan CW, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–477. [PMC free article] [PubMed]
4. Parsons DW, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–1812. [PMC free article] [PubMed]
5. Hahn WC, et al. Creation of human tumour cells with defined genetic elements. Nature. 1999;400(6743):464–468. [PubMed]
6. Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev Cancer. 2011;11(3):161–176. [PubMed]
7. Kim NW, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011–2015. [PubMed]
8. Huang FW, et al. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957–959. [PMC free article] [PubMed]
9. Bell RJ, et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 2015;348(6238):1036–1039. [PMC free article] [PubMed]
10. Killela PJ, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 2013;110(15):6021–6026. [PubMed]
11. Heidenreich B, et al. TERT promoter mutations in cancer development. Curr Opin Genet Dev. 2014;24:30–37. [PubMed]
12. Heidenreich B, et al. TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget. 2015;6(12):10617–10633. [PMC free article] [PubMed]
13. Labussiere M, et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 2014;83(13):1200–1206. [PubMed]
14. Barretina J, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–607. [PMC free article] [PubMed]
15. Mao DD, et al. A CDC20-APC/SOX2 signaling axis regulates human glioblastoma stem-like cells. Cell Rep. 2015;11(11):1809–1821. [PMC free article] [PubMed]
16. Eckel-Passow JE, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–2508. [PMC free article] [PubMed]
17. Simon M, et al. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2015;17(1):45–52. [PMC free article] [PubMed]
18. Sahm F, et al. TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. 2016;108(5) doi: 10.1093/jnci/djv377. [PMC free article] [PubMed] [Cross Ref]
19. Goutagny S, et al. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014;24(2):184–189. [PubMed]
20. Cancer Genome Atlas Research network et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481–2498. [PMC free article] [PubMed]
21. Stewart SA, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA. 2002;99(20):12606–12611. [PubMed]
22. Huang FW, et al. TERT promoter mutations and monoallelic activation of TERT in cancer. Oncogenesis. 2015;4:e176. [PMC free article] [PubMed]
23. Shankar GM, et al. Rapid intraoperative molecular characterization of glioma. JAMA Oncol. 2015;1(5):662–667. [PMC free article] [PubMed]
24. Arita H, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 2013;126(2):267–276. [PubMed]
25. Greider CW. Molecular biology. Wnt regulates TERT— putting the horse before the cart. Science. 2012;336(6088):1519–1520. [PubMed]